You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for PROCTOFOAM HC


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for PROCTOFOAM HC

Vendor Vendor Homepage Vendor Sku API Url
BenchChem ⤷  Start Trial B1220082 ⤷  Start Trial
THE BioTek ⤷  Start Trial bt-1555504 ⤷  Start Trial
J&H Chemical Co.,ltd ⤷  Start Trial JH901854 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for PROCTOFOAM HC

Last updated: February 26, 2026

What are the primary API sources for PROCTOFOAM HC?

PROCTOFOAM HC contains hydrocortisone acetate as its active pharmaceutical ingredient (API). This corticosteroid relieves inflammation and itching associated with hemorrhoids and other anorectal conditions. The API sourcing involves a global supply chain with key regions, manufacturers, and regulatory considerations.

Who are the leading API manufacturers for hydrocortisone acetate?

Major API suppliers for hydrocortisone acetate include:

  • Dr. Reddy's Laboratories (India): Operates multiple manufacturing facilities compliant with GMP standards; supplies to global markets.
  • Hubei EastLake Pharmaceutical (China): Produces hydrocortisone acetate with approval from the Chinese FDA, exporting to various regions.
  • Dow Pharmaceutical Sciences (United States): Historically supplies hydrocortisone acetate, emphasizing pharmaceutical-grade APIs.
  • Ningbo Inno Pharmchem Co., Ltd. (China): Specializes in corticosteroid APIs, including hydrocortisone acetate.
  • Xianju Pharmaceutical (China): Manufactures corticosteroids for domestic and export markets.

What regions dominate API production for hydrocortisone acetate?

Region Market Share Notable Manufacturers Regulatory Agencies
China 50% Hubei EastLake, Ningbo Inno Pharmchem, Xianju Pharmaceutical NMPA (formerly CFDA)
India 30% Dr. Reddy's Laboratories DCGI, GMP-compliant facilities
United States 10% Dow Pharmaceutical Sciences FDA, cGMP standards
Europe 10% Contract manufacturing, niche suppliers EMA, EMA-regulated facilities

How do regulatory standards influence API sourcing?

API sources must meet Good Manufacturing Practices (GMP) requirements, with certifications from regulatory agencies such as:

  • U.S. Food and Drug Administration (FDA): Ensures API quality for U.S. marketed drugs.
  • European Medicines Agency (EMA): Certifies APIs for European markets.
  • National Medical Products Administration (NMPA): Approves Chinese API manufacturers.
  • Drug Controller General of India (DCGI): Oversees Indian API manufacturers.

Manufacturers holding GMP certification are preferred for supplying APIs for pharmaceuticals like PROCTOFOAM HC, which is formulated under strict quality control.

What are the key considerations for sourcing hydrocortisone acetate APIs?

  • Quality compliance: API must meet pharmacopeial standards (USP, EP, BP).
  • Supply stability: Long-term supply agreements mitigate shortages.
  • Price competitiveness: Market fluctuations impact procurement costs.
  • Regulatory approvals: Suppliers with certified facilities reduce compliance risks.
  • Traceability: Clear documentation facilitates regulatory audits.

How does API sourcing impact PROCTOFOAM HC manufacturing?

Sourcing from approved and reliable API suppliers ensures product quality, regulatory compliance, and consistent supply. Disruptions in the API supply chain can lead to manufacturing delays, increased costs, or recalls. Manufacturers typically maintain a dual-supplier strategy to mitigate risk.

Summary table: Key API suppliers for hydrocortisone acetate

Supplier Location Certification Capacity (kg/year) Market Focus
Dr. Reddy's Laboratories India GMP, ISO 500,000 Global (especially North America and Europe)
Hubei EastLake Pharmaceutical China GMP, NMPA 300,000 China, Asia, export markets
Dow Pharmaceutical Sciences US cGMP, ISO 150,000 U.S., Europe
Ningbo Inno Pharmchem Co. China GMP, ISO 250,000 Asia, emerging markets
Xianju Pharmaceutical China GMP, NMPA 200,000 China, Southeast Asia

Key Takeaways

  • Hydrocortisone acetate APIs for PROCTOFOAM HC predominantly come from Chinese and Indian manufacturers.
  • Quality and regulatory compliance are mandatory; GMP certification is critical.
  • Supply chain stability influences manufacturing continuity.
  • Major suppliers include Dr. Reddy's (India) and several Chinese firms.
  • Regulatory agencies such as the FDA, EMA, NMPA, and DCGI oversee GMP compliance.

FAQs

Q1: Are there any alternative API sources for hydrocortisone acetate?
A1: Smaller or emerging suppliers in Europe and other regions may provide APIs, but they must meet strict regulatory standards.

Q2: How does GMP certification impact API acceptance?
A2: GMP certification ensures manufacturing quality, reducing risks of contamination, batch variability, and regulatory rejection.

Q3: Can synthetic routes of hydrocortisone acetate influence API sourcing?
A3: Yes. Different synthetic processes can result in varying impurity profiles, affecting supplier selection.

Q4: What are the risks of relying on single-source API suppliers?
A4: Single sourcing increases vulnerability to supply disruptions, regulatory issues, or quality concerns.

Q5: How do geopolitical factors affect API sourcing for hydrocortisone acetate?
A5: Tariffs, trade restrictions, or export controls can impact supply availability and costs, especially from China and India.


References

[1] US Food and Drug Administration (FDA). (2022). Guidance for Industry: API Quality Standards.
[2] European Medicines Agency (EMA). (2022). Good Manufacturing Practice (GMP) guidelines.
[3] National Medical Products Administration (NMPA). (2022). Regulations on Pharmaceutical Manufacturing.
[4] Drug Controller General of India (DCGI). (2022). API Regulatory Framework.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.